Several other brokerages also recently weighed in on CEMI. Colliers Securities restated a “neutral” rating on shares of Chembio Diagnostics in a research note on Tuesday, March 22nd. Zacks Investment Research downgraded Chembio Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 9th.
NASDAQ CEMI opened at $0.62 on Thursday. The stock’s 50-day moving average price is $0.76 and its 200-day moving average price is $1.28. The company has a quick ratio of 2.74, a current ratio of 3.59 and a debt-to-equity ratio of 0.52. Chembio Diagnostics has a 52 week low of $0.53 and a 52 week high of $7.34. The company has a market capitalization of $18.58 million, a P/E ratio of -0.45 and a beta of 1.73.
Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Chembio Diagnostics by 35.1% in the 4th quarter. Geode Capital Management LLC now owns 274,422 shares of the company’s stock valued at $312,000 after purchasing an additional 71,352 shares in the last quarter. BlackRock Inc. grew its stake in shares of Chembio Diagnostics by 34.1% during the 3rd quarter. BlackRock Inc. now owns 267,208 shares of the company’s stock valued at $668,000 after buying an additional 67,959 shares during the period. Morgan Stanley grew its stake in shares of Chembio Diagnostics by 235.8% during the 3rd quarter. Morgan Stanley now owns 122,123 shares of the company’s stock valued at $305,000 after buying an additional 85,756 shares during the period. Virtu Financial LLC boosted its position in Chembio Diagnostics by 506.7% during the 4th quarter. Virtu Financial LLC now owns 119,238 shares of the company’s stock worth $136,000 after purchasing an additional 99,585 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in Chembio Diagnostics in the 4th quarter valued at about $105,000. Institutional investors own 13.27% of the company’s stock.
About Chembio Diagnostics (Get Rating)
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.
- Get a free copy of the StockNews.com research report on Chembio Diagnostics (CEMI)
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.